Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calcimimetics--fooling the calcium receptor.

Eberhard Ritz

    Pediatric Nephrology (Berlin, Germany)
    |November 2, 2004
    PubMed
    Summary

    New small molecules can target the calcium-sensing receptor to control parathyroid hormone levels. Calcimimetics effectively treat hyperparathyroidism by lowering PTH and, in some cases, calcium and phosphate.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Different Relevance of Peripheral, Central or Nighttime Blood Pressure Measurements in the Prediction of Chronic Kidney Disease Progression in Patients with Mild or No-Proteinuria.

    Kidney & blood pressure research·2018
    Same author

    Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120.

    Clinical and experimental nephrology·2017
    Same author

    Morbidity, mortality and quality of life in the ageing haemodialysis population: results from the ELDERLY study.

    Clinical kidney journal·2016
    Same author

    The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials.

    BMC nephrology·2016
    Same author

    Bariatric surgery and the kidney-much benefit, but also potential harm.

    Clinical kidney journal·2016
    Same author

    Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial.

    Journal of hypertension·2016

    Area of Science:

    • Endocrinology
    • Molecular Biology
    • Pharmacology

    Background:

    • The calcium-sensing receptor (CaSR) in parathyroid cells regulates parathyroid hormone (PTH) secretion.
    • Modulating CaSR activity offers therapeutic potential for disorders of calcium homeostasis.

    Discussion:

    • Organic small molecules, including calcimimetics and calciolytics, can modulate CaSR activity.
    • Calcimimetics increase receptor sensitivity to calcium, suppressing PTH secretion.
    • Calciolytics decrease receptor sensitivity, stimulating PTH secretion.

    Key Insights:

    • Calcimimetics are effective in treating primary and secondary hyperparathyroidism, lowering PTH levels with few side effects.
    • A key advantage of calcimimetics in secondary hyperparathyroidism is the simultaneous reduction of serum calcium and phosphate levels.
    • This suggests a targeted approach for managing complex endocrine disorders.

    Outlook:

    • Further research into small molecule modulators of CaSR could lead to novel therapeutic strategies.
    • Developing more selective calcimimetics and calciolytics may improve treatment outcomes for various hyperparathyroid conditions.
    • Investigating the long-term effects and potential applications in other calcium-related diseases is warranted.

    Related Experiment Videos